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HIGH-ACTIVITY MUTANTS OF
BUTYRYLCHOLINESTERASE FOR
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Subject matter described herein Was made With govem
ment support under Grant Number R01DA013930 aWarded

by the National Institute on Drug Abuse (NIDA) of the
National Institutes of Health (NIH). The government has
certain rights in the described subject matter.
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FIELD OF THE INVENTION

+

The present invention relates to butyrylcholinesterase vari
ocH3

ant polypeptides, and in particular, butyrylcholinesterase
mutants having amino acid substitutions.

30

OH

BACKGROUND OF THE INVENTION

Only 5% of the cocaine is deactivated through oxidation by
the liver microsomal cytochrome P450 system. Cocaine

Cocaine abuse is a major medical and public health prob
lem that continues to defy treatment. The disastrous medical
and social consequences of cocaine addiction, such as violent

35

ester, Whereas the oxidation produces norcocaine. The
metabolite ecgonine methyl ester is a biologically inactive
metabolite, Whereas the metabolite norcocaine is hepatotoxic

crime, loss in individual productivity, illness and death, have
made the development of an effective pharmacological treat
ment a high priority. HoWever, cocaine mediates its reinforc

ing and toxic effects by blocking neurotransmitter reuptake
and the classical pharmacodynamic approach has failed to
yield small-molecule receptor antagonists due to the di?icul

and a local anesthetic. BChE is synthesiZed in the liver and
40

45

is butyrylcholinesterase (BChE)-catalyZed hydrolysis at the
benZoyl ester group (Scheme 1).
Scheme 1. Schematic representation of
BChE-catalyzed hydrolysis at the benzoyl ester group.

Widely distributed in the body, including plasma, brain, and
lung. Extensive experimental studies in animals and humans
demonstrate that enhancement of BChE activity by adminis
tration of exogenous enZyme substantially decreases cocaine

ties inherent in blocking a blocker. An alternative to receptor

based approaches is to interfere With the delivery of cocaine
to its receptors and accelerate its metabolism in the body.
The dominant pathWay for cocaine metabolism in primates

hydrolysis at benZoyl ester group yields ecgonine methyl

half-life.
Enhancement of cocaine metabolism by administration of
BChE has been recogniZed to be a promising pharmacoki

netic approach for treatment of cocaine abuse and depen

50

dence. HoWever, the catalytic activity of this plasma enZyme
is three orders-of-magnitude loWer against the naturally
occurring (—)-cocaine than that against the biologically inac
tive (+)-cocaine enantiomer. (+)-cocaine can be cleared from
plasma in seconds and prior to partitioning into the central
nervous system (CNS), Whereas (—)-cocaine has a plasma

half-life of approximately 45-90 minutes, long enough for
manifestation of the CNS effects Which peak in minutes.

Hence, BChE mutants With high activity against (—)-cocaine
are highly desired for use in humans. Although some BChE

ocH3
BChE
60

mutants With increased catalytic activity over Wild-type
BChE have previously been generated, there exists a need for
mutant BChE With even higher catalytic activity. Thus, prior
mutants provide limited enhancement in catalytic activity
over Wild-type BChE.

Previous studies such as (a) Masson, P.; Legrand, P.; Bar
65

tels, C. F.; Froment, M-T.; Schopfer, L. M.; Lockridge, 0.
Biochemistry 1997, 36, 2266 (b) Masson, P.; Xie, W., Fro
ment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lock
ridge, O. Biochim. Biophys. Acla 1999, 1433, 281, (c) Xie,

US 8,399,644 B1
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4

W.; Altamirano, C. V.; Bartels, C. E; Speirs, R. J.; Cashman,
J. R.; Lockridge, 0. Mol. Pharmacol. 1999, 55, 83, (d) Duy

tions of cocaine binding With Wild-type BChE and the reac
tion coordinate calculations point to some amino acid resi
dues that might need to be mutated for the purpose of

sen, E. G.; Bartels, C. E; Lockridge, O. J. Pharmacol. Exp.

Ther. 2002, 302, 751, (e) Nachon, E; Nicolet,Y.; V1guie, N.;

improving the catalytic activity for (—)-cocaine hydrolysis, it

Masson, P.; Fontecilla-Camps, J. C.; Lockridge, 0. Eur. J.
Biochem. 2002, 269, 630, (f) Zhan, C.-G.; Landry, D. W. J.
Phys. Chem. A 2001, 105, 1296; Berkman, C. E.; Underiner,
G. E.; Cashman, J. R. Biochem. Pharmcol. 1997, 54, 1261;

remained unknoWn Which exact amino acid mutations Will

result in a BChE With a higher catalytic activity for (—)
cocaine.
Computational studies of Wild-type BChE and cocaine
from Sun, et al, based on a “homology model,” suggest that

(g) Sun, H.; YaZal, J. E.; Lockridge, O.; Schopfer, L. M.;
Brimijoin, S.; Pang,Y.-P. J. Biol. Chem. 2001, 276, 9330, (h)
Sun, H.; Shen, M. L.; Pang,Y. P.; Lockridge, O.; Brimijoin, S.
J. Pharmacol. Exp. Then 2002, 302, 710, Sun, H.; Pang,Y.
P.; Lockridge, O.; Brimijoin, S. Mol. Pharmacol. 2002, 62,
220 (hereinafter “Sun et al”); and (j) Zhan, C.-G.; Zheng, E;
Landry, D. W. J Am. Chem. Soc. 2003, 125, 2462 (hereinafter

the rate-determining step for BChE-catalyzed hydrolysis of
cocaine is the rotation of the cocaine in the active site of

BChE. By decreasing the hindrance of the rotation, the rate of
the hydrolysis may be enhanced. Sun, et al describes creating
an A328W/Y332A BChE mutant by: (1) replacing Tyr332
5

“Zhan et al”), herein all incorporated by reference, suggested
that, for both (—)-cocaine and (+)-cocaine, the BChE-sub

tion that impede rotation,” and (2) replacing Ala328 With Trp

20

“to provide a cation-rt interaction to restore substrate a?inity
lost in disabling the J'lZ-J'IZ interaction.”
Sun et al studied the A328W/Y332A BChE mutant using
enZyme assays and kinetics. In vitro studies Were conducted
using human plasma and in vivo studies Were conducted
using male Sprague-DaWley rats. The mutant Was found to
have enhanced catalytic properties. The mutant Was further

25

(3D) structure of A328W/Y332A Was generated from the

strate binding involves tWo different types of complexes:

non-prereactive and prereactive BChE-substrate complexes.
Whereas the non-prereactive BChE-cocaine complexes Were
?rst reported by Sun et al, Zhan et al Were the ?rst reporting
the prereactive BChE-cocaine complexes and reaction coor
dinate calculations, disclosed in Zhan et al.
It Was demonstrated that (—)/(+)-cocaine ?rst slides doWn
the substrate-binding gorge to bind to W82 and stands verti
cally in the gorge betWeen D70 and W82 (non-prereactive
complex) and then rotates to a position in the catalytic site
Within a favorable distance for nucleophilic attack and

studied using molecular modeling. The three dimensional

computationally generated 3D model of Wild-type BChE and
changing the relevant residues using commercially available
softWare. Cocaine Was docked to the catalytic gorge of the

hydrolysis by S198 (prereactive complex). In the prereactive
complex, cocaine lies horizontally at the bottom of the gorge.
The main structural difference betWeen the BChE-(—)-co

30

caine complexes and the corresponding BChE-(+)-cocaine
ester group. Reaction coordinate calculations revealed that

It should be noted that all prior computational techniques
35

(+)-cocaine is the chemical reaction process, Whereas for
sis of the structural changes from the non-prereactive com
40

clues for the rational design of BChE mutants With improved

catalytic activity for (—)-cocaine.
Previous molecular dynamics (MD) simulations of prere
active BChE-cocaine binding Were limited to Wild-type

45

BChE. Even for the non-prereactive BChE-cocaine complex,
only one mutant (A328W/Y332A) BChE binding With (—)
cocaine Was simulated and its catalytic activity for (—)-co

cocaine hydrolysis activity. For example, mutants include
F227A/A328W; F227A/S287G/A328W; A119S/S287G/
A328W; A328W/Y332M/S287G/F227A, A199S/F227A/S/
50

(—)- or (+)-cocaine binding With a mutant BChE. In addition,
all previous computational studies of Sun et al and Zhan et al

287G/A328W and A119S/F227A/S287G/A328W/Y332M.

The mutants have varying increases in catalytic activity, up to
100-fold increase relative to Wild-type BChE.

of BChE interacting With cocaine Were performed based on a

There exists a need in the art for determining Which pro

homology model of BChE When three-dimensional (3D)
X-ray crystal structure Was not available for BChE, as taught

complicated catalytic reaction process. As it is Well-knoWn, it
is particularly challenging to model and simulate the detailed
reaction pathWay and predict the kinetics of such an enZy
matic reaction.
US. Patent Application Publication Nos. 2004/0121970;
2004/0120939; and 2003/0153062, describe 20+BChE
mutants, or “variants,” from human and other animals, each
having from one to six amino acid alterations and increased

caine Was reported by Sun et al. No MD simulation Was

performed on any prereactive enzyme-substrate complex for

(molecular docking and molecular dynamics simulation)
used by other researchers are based on an empirical force ?eld
Which cannot be used to perform any necessary reaction
coordinate calculation for the detailed understanding of the

(—)-cocaine the change from the non-prereactive complex to
the prereactive complex is rate determining. A further analy
plex to the prereactive complex reveals speci?c amino acid
residues hindering the structural changes, providing initial

mutant BChE using other commercially available softWare.
The cocaine-enzyme complex Was re?ned by molecular
dynamic simulation. The data generated by the molecular
modeling studies Were consistent With enZyme assays and
kinetic data.

complexes exists in the relative position of the cocaine methyl

the rate-determining step of BChE-catalyzed hydrolysis of

With Ala, “to reduce the steric hindrance and the J'lZ-J'IZ interac

55

by Nicolet,Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps,

posed mutant BChEs should have ever increasing catalytic
activity and for generating those mutants Which should have

enhanced catalytic activity.

J. C.; Nachon, F. J Biol. Chem. 2003, 278, 41141 (hereinafter
“Nicolet et al”), recently reported 3D X-ray crystal structures

SUMMARY OF THE INVENTION

of BChE. As expected, the structure of BChE is similar to a

previously published theoretical model of this enZyme and to
the structure of acetylcholinesterase.
The main difference betWeen the experimentally deter

60

mined BChE structure and its model Was found at the acyl

binding pocket (acyl loop) that is signi?cantly bigger than
expected. It is unclear Whether the structural difference at the

acyl binding pocket signi?cantly affect BChE binding With
(—)-cocaine and (+)-cocaine. Although previous MD simula

The present invention includes ?ve novel human BChE

mutants that have unexpected increased catalytic e?iciency
for cocaine hydrolysis. The mutants have various unique
amino acid residue substitutions Which provide the surprising
65

enhanced catalytic activity. These mutants are (1) A199S/
A328W/Y332G mutant (SEQ ID NO: 2), Which has a

approximately 65-fold improved catalytic ef?ciency against
(—)-cocaine; (2) A199S/F227A/A328W/Y332G mutant

US 8,399,644 B1
5

6

(SEQ ID NO: 8), Which has an approximately 148-fold

sequence selected from the group consisting of SEQ ID NOS:

improved catalytic ef?ciency against (—)-cocaine; (3) A1 99S/

2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30.

S287G/A328W/Y332G mutant (SEQ ID NO: 14), Which has

The present invention in another form thereof concerns a

an approximately 456-fold improved catalytic e?iciency

nucleic acid molecule comprising a nucleic acid sequence
Which encodes a butyrylcholinesterase variant peptide, the
nucleic acid sequence selected from the group consisting of

against (—)-cocaine; (4) A199S/F227A/S287G/A328W/
Y332G mutant (SEQ ID NO: 20), Which has an approxi

SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27,

mately 1,003-fold improved catalytic e?iciency against (—)

and 29.
The present invention in another form thereof concerns a

cocaine; and (5) A199S/F227A/S287G/A328W/E441D
mutant (SEQ ID NO: 26), Which has an approximately 445

pharmaceutical composition comprising a butyrylcholinest

fold improved catalytic e?iciency against (—)-cocaine.

erase variant polypeptide comprising an amino acid sequence

In addition, the aforementioned mutant amino acid
sequences can be truncated Without substantially affecting
the catalytic activity so that amino acid residues 1-67 and
443-574 can be removed Without substantially affecting the

selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8,
10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30; and a suitable

pharmaceutical carrier.
The present invention in another form thereof concerns a

catalytic activity of the enZyme. SEQ ID NOS: 4, 10, 16, 22

method for treating a cocaine-induced condition comprising

and 28 are the amino acid sequences for residue 68-142

administering to an individual an effective amount of butyryl

corresponding to mutants 1-5, respectively. In addition, With

cholinesterase variant peptide having an amino acid sequence

regard to mutants 1-4, it Was found that amino acid residues
before 117 and after 438 could be removed Without substan

20

tially changing the activity of the mutant enZymes, resulting
in truncated amino acid sequences having SEQ ID NOS: 6,
12, 18 and 24, respectively. Finally With regard to mutant 5,

cocaine concentration.
The present invention is another form thereof concerns a

method for treating a cocaine induced condition comprising

amino acid residues before 117 and after 441 could be

removed Without substantially changing its activity resulting

administering to an individual an effective amount of a phar
25

maceutical composition comprising a butyrylcholinesterase
variant having an amino acid sequence selected from the

in SEQ ID NO: 30.
These aforementioned truncated sequences all of With
similar catalytic activity is based on protein structures.
Further, the present invention is directed to a novel and

unique pharmaceutical composition Which comprises a
butyrylcholinesterase variant, namely mutants 1-5, along

selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8,
10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to loWer blood

group consisting ofSEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18,
20, 22, 24, 26, 28, and 30, and suitable pharmaceutical carrier
of claim 3 to an individual in an effective amount to loWer
30

blood cocaine concentration.
The present invention in yet another form thereof concerns

With a suitable pharmaceutical carrier. The pharmaceutical

a method for generating butyrylcholinesterase mutants. The

composition can be administered to an individual in an effec

method includes generating an initial structure of the transi
tion state structure for the rate-determining step of the

tive amount to loWer the patient’s cocaine blood concentra

tion and in particular (—)-cocaine blood concentration.

35

cocaine hydrolysis catalyZed by a possible butyrylcholinest

In addition, the present invention is directed to a novel and

erase mutant. A suf?ciently long time molecular dynamics

unique method for developing mutants Which have enhanced
catalytic ef?ciency. The generation method includes both a

simulation is performed on the transition state structure in
Water to have a stable molecular dynamics trajectory. The

molecular dynamics trajectory is analyZed and the hydrogen

computational portion and an experimental portion. With
regard to the computational portion, a variety of state of the

40

art computational techniques including molecular modeling,
molecular dynamics (MD) simulations and hybrid quantum
mechanical/molecular mechanical (QM/MM) calculations,
provide a virtual screening of possible BChE mutants. This
virtual screening predicts Which mutation Will lead to a more
stable transition state for a rate-determining step compared to

45

(—)-cocaine benZyl ester and the Wild-type butyrylcholinest
erase, optionally, hybrid quantum mechanical/molecular
mechanical (QM/MM) geometry optimiZation is performed

the corresponding separated reactants, i.e., free cocaine and
free enZyme. The more stable the transition state, the loWer

the energy barrier, and the higher the catalytic ef?ciency.
Following the computational portion, an experimental test is

bonding energies are estimated betWeen the carboxyl oxygen
of the (—)-cocaine benZyl ester and the oxyanion hole of the
possible butyrylcholinesterase mutant. If the overall hydro
gen binding energy betWeen the carboxyl oxygen of the (—)
cocaine benZyl ester and the possible butyrylcholinesterase
mutant, in the transition state, is stronger than the overall
hydrogen binding energy betWeen the carboxyl oxygen of the

portion. The experimental test includes site-directed

to re?ne the molecular dynamics-simulated structure, the
hydrogen binding energies are calculated and the energy bar
rier is evaluated. Finally, the butyrylcholinesterase mutant is

mutagenesis, protein expression, and enZyme activity assay.

generated.

50

then conducted on the possible mutants of the computation

In various alternative embodiments, the generating an ini

The experimental tests are conducted on mutants Which are

predicted to have a high catalytic ef?ciency against (—)-co

55

tion coordinate calculations for the Wild-type butyrylcho
linesterase. The generating butyrylcholinesterase mutant

caine than the Wild-type BChE and/or other knoWn BChE

mutants against (—)-cocaine. Thus, the present method iden
ti?es or predicts mutants having high catalytic activity for

includes performing site-directed mutagenesis on a nucleic

cocaine hydrolysis by performing molecular modeling and
MD simulations on the transition state structures of possible
mutants of BChE. This method is an improvement over tra

acid sequence Which includes Wild-type butyrylcholinest
60

The present invention in one form, concerns a butyrylcho

linesterase variant peptide comprising an amino acid

erase to generate the mutant butyrylcholinesterase nucleic

acid sequence. Using the mutant butyrylcholinesterase
nucleic acid sequence, the protein encoded by the mutant
nucleic acid sequences is expressed to produce mutant
butyrylcholinesterase and catalytic activity assay is per

ditional random-search approaches, Which, given the com
plex catalytic mechanism of cocaine hydrolysis, makes it
dif?cult to improve the catalytic activity of BChE for cocaine

hydrolysis.

tial structure of the transition state structure is based on reac

65

formed on the mutant butyrylcholinesterase.

The hybrid quantum mechanical/molecular mechanical
geometry optimiZation may include calculating the hydrogen

US 8,399,644 B1
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binding energies and evaluating the energy barriers only if the
overall hydrogen binding energy betWeen the carboxyl oxy
gen of the (—)-cocaine benZyl ester and the possible butyryl

FIG. 4A depicts the (—)-cocaine rotation in the active site of
A328W/Y332A; FIG. 4B depicts the (—)-cocaine rotation in
the active site of A328W/Y332G BChE from the non-preac

tive complex to the prereactive complex; and FIG. 4C depicts

cholinesterase mutant, in the transition state, is stronger than

knoWn butyrylcholinesterase mutants against (—)-cocaine.

the (—)-cocaine rotation in the active site of Wild-tune BChE.

In yet another alternative further embodiment, the method
for generating butyrylcholinesterase mutants further includes

versus the time in the simulated TS1 structure for (—)-cocaine

FIG. 5A is a plot of the key internuclear distances (in A)

hydrolysis catalyZed by A328W/Y332A; and FIG. 5B for

determining the rate-limiting step in the hydrolysis of (—)

A199S/A328W/Y332G BChE.

cocaine by the possible butyrylcholinesterase mutant by con
ducting molecular dynamics simulations and quantum

FIG. 6 is a plot of key internuclear distances (in A) versus
the time in the simulated TS1 structure for (—)-cocaine

mechanical/molecular mechanical calculations relating to the
transition states for other reaction steps betWeen (—)-cocaine

hydrolysis catalyZed by A199S/S287G/A328W/Y332G
BChE.

by the possible butyrylcholinesterase mutant and calculating
respective energy barriers, thereby establishing Which of the

DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENTS

reaction steps is the rate-determining one.
BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 are plots of distances in the MD simulation (—)
cocaine binding With A328W/Y332G BChE versus the simu

lation time, along With root-mean-square deviation (RMSD)
in the enzyme-substrate complexes Where FIG. 1A represents
the non-prereactive enZyme-substrate complexes; and FIG.
1B represents the prereactive enzyme-substrate complexes in

20

E441D each have a signi?cantly higher catalytic e?iciency.
The second improvement is concerning the mutant designing
25

accordance With the present invention.
FIG. 2 shoWs the binding of structures of the simulated

sequences, SEQ ID NOS: 2, 8, 14, 20, and 26, respectively,

BChE binding With tWo entomers of cocaine in Which FIG.

FIG. 3A shoWs the (—)-cocaine rotation in the BChE active
site for the non-prereactive complex to the prereactive com

plex hindered by some residues at positions Y332, A328, and
F329 residues in the non-prereactive complexes Which are
signi?cantly different from the corresponding positions in the
prereactive complex; and FIG. 3B shoWs the (+)-cocaine
rotation in the BChE active site Where none of the aforemen

or discovering process.
The BChE mutants 1-5 have full length amino acid

Which are encoded by nucleic acid sequences having SEQ ID

non-prereactive and prereactive complexes of Wild-type
2A depicts BChE (—)-cocaine non-prereactive complex; FIG.
2B depicts BChE (—)-cocaine prereactive complex, FIG. 2C
depictes BChE (+)-cocaine non-prereactive complex; and
FIG. 2D depicts BChE (+)-cocaine prereactive complex.

The present invention has tWo major improvements over
the prior art. The ?rst is the presently discovered BChE
mutants, mutant 1, A199S/A328W/Y332G; mutant 2,
A199S/F227A/A328W/Y332G; mutant 3, A199S/S287G/
A328W/Y332G; mutant 4, A199S/F227A/S287G/A328W/
Y332G; and mutant 5, A199S/F227A/S287G/A328W/

30

NOS: 1, 7, 13, 19, and 25, respectively. Table 1 summarizes
the catalytic ef?ciency against (—)-cocaine for the ?ve
mutants.

In addition to the full length BChE mutants, the respective
amino acid sequence can be truncated Without substantially

affecting the respective catalytic activity. With all mutants,
residues 1-67 and 443-574 can be removed Without substan
35

tially affecting the catalytic activity of the respective mutant
BChE. Further, With regard to mutant 1-4, amino acids 1-1 16
and 439-574 canbe omitted Without substantially affecting its

respective catalytic activity. With regard to mutant 5, amino
acid residues 1-116 and 442-574 can be omitted Without
40

tioned residues hinders the (+)-cocaine rotation in the BChE
active site from the non-prereactive complex to the prereac
tive complex in accordance With the present invention.

substantially affecting its catalytic activity. Table 1 also pro
vides a summary of amino acid SEQ ID NOS and correspond
ing nucleic acid SEQ ID NOS for the aforementioned trun
cated mutant BChE sequences.

TABLE 1
Partially Truncated
Nucleic Acid

Amino
Acid
Mutant SubstiNumber tuting
1

2

3

4

A199S/
A328W/
Y332G
A199S/
F227N
A328W/
Y332G
A199S/
S287G/
A328W/
Y332G
A199S/
F227N
S287G/
A328W/

SEQ ID NO

Amino
Sequence
SEQ ID NO. for Corresponding To SEQ ID NO.
Nucleic
Acid Corresponding To Amino Acid
Amino Acid
for Amino
Acid SEQ SEQ ID
Amino Acid
Residues
Residues
Acid Residues
ID NO.

NO.

Catalytic
Ef?ciency
Against

Residues 68-442

68-442

117-43 8/441 *

117-438/441*

(—)-cocaine

1

2

3

4

5

6

65-fold

7

8

9

10

11

12

148-fold

13

14

15

16

17

18

456-fold

19

20

21

22

22

24

1,003-fold

25

26

27

28

29

30

445-fold

Y332G

5

A199S/
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TABLE l-continued
Partially Truncated
Nucleic Acid

Amino
Acid
Mutant SubstiNumber tuting

SEQ ID NO

Amino
Sequence
SEQ ID NO. for Corresponding To
Nucleic
Acid Corresponding To Amino Acid
Amino Acid
Acid SEQ SEQ ID
Amino Acid
Residues
Residues
ID NO.

NO.

Residues 68-442

68-442

117-43 8/441 *

SEQ ID NO.
for Amino
Acid Residues

Catalytic
Ef?ciency
Against

117-43 8/441*

(—)-cocaine

(*Amino acid residues 117-438 for mutants 1-4 and residues 117-441 for mutant 5.)

The BChE variant polypeptide, e.g., SEQ ID NOS: 2, 4, 6,
8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30 can be

hydrogen binding energies are estimated between the car
boxyl oxygen of the (—)-cocaine benzoyl ester and the oxya
nion hole of the possible BChE mutant. If the overall hydro

formulated in a pharmaceutical composition along with a
suitable pharmaceutical carrier known to one skilled in the
art.

The present BChE variant polypeptides can be used in
treating a cocaine-induced condition by administering to an

20

zoyl ester and the wild-type BChE, hybrid quantum mechani
cal/molecular mechanical (QM/MM) geometry optimization

individual, an effective amount of one of the BChE variant

polypeptides, i.e., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18,
20, 22, 24, 26, 28, and 30, to lower blood cocaine concentra
tion. The BChE variant polypeptide may be administered in
the form of a pharmaceutical composition in which the BChE
variant is included with a suitable pharmaceutical carrier.
Treatment of a cocaine induced condition using one of the
aforementioned BChE variant polypeptides can be done in
accordance with Zhan et al., page 2463.
The preferred dose for administration of a butyrylcho
linesterase or peptide composition in accordance with the
present invention is that amount which will be effective in

25

30

mutants and, when needed, other reaction steps are modeled
and calculated using molecular dynamics simulations and

QM/MM calculations. Following this modeling, mutant
35

identi?ed by computational analysis and generated by site
40

is produced. Thus, the exact amount of the enzyme or a

particular agent that is required will vary from subject to
subject, depending on the species, age, and general condition
of the subject, the severity of the condition being treated, the
particular carrier or adjuvant being used and its mode of

BChE’ s are created using site-directed mutagenesis followed

by protein expression. The aformentioned ?ve mutants were

is intended to mean a nontoxic but su?icient amount of the

agent, such that the desired prophylactic or therapeutic effect

is performed to re?ne the molecular dynamics-simulated
structure, the hydrogen binding energies are calculated and
the energy barrier is evaluated. The QM/MM calculations
make the computational predictions more reliable. Finally,
the BChE mutant is generated.
With regard to the molecular dynamics (MD) simulations
and quantum mechanical/molecular mechanical (QM/MM)
calculations, the ?rst chemical reaction step of (—)-cocaine

hydrolysis catalyzed by butyrylcholinesterase (BChE)

lowering (—)-cocaine concentration in a patient’s blood
stream, and one would readily recognize that this amount will
vary greatly depending on the nature of cocaine consumed,
e.g., injected or inhaled, and the condition of a patient. An
“effective amount” of butyrylcholinesterase mutant or phar
maceutical agent to be used in accordance with the invention

gen binding energy between the carboxyl oxygen of the (—)
cocaine benzoyl ester and the possible BChE mutant, in the
transition state, is stronger than the overall hydrogen binding
energy between the carboxyl oxygen of the (—)-cocaine ben

directed mutagenesis which have signi?cantly enhanced (—)
cocaine hydrolysis catalytic ef?ciency compared with wild
type BChE.
In the present method computational analysis in the form
of molecular modeling of a potential BChE mutant and MD
simulations and QM/MM calculations provide virtual screen

45

administration, and the like. Similarly, the dosing regimen

ing of possible BChE mutants which have predicted enhanced
catalytic activity for (—)-cocaine. For example, the MD simu
lations and QM/MM calculations predict which mutation will

should also be adjusted to suit the individual to whom the
composition is administered and will once again vary with

lead to a more stable transition state for the rate determining

age, weight, metabolism, etc. of the individual. Accordingly,
the “effective amount” of any particular butyrylcholinest

free cocaine and free possible mutant BChE, where the more

step compared to the corresponding separated reagents, i.e.,
50

stable transition state leads to a lower energy barrier and

erase composition will vary based on the particular circum
stances, and an appropriate effective amount may be deter
mined in each case of application by one of ordinary skill in

higher predicted catalytic el?ciency. Only after the computa
tional analysis predicts enhanced catalytic ef?ciency, is site

the art using only routine experimentation.

acid sequence to generate a mutant nucleic acid sequence
which is then used to express a mutant BChE protein. The

A unique method was used to determine potential BChE

directed mutagenesis conducted on wild-type BChE nucleic
55

mutants with projected increased catalytic activity for the
hydrolysis of cocaine. The method provides a unique
approach which ?rst models the potential BChE mutant inter
action with cocaine followed by generating the BChE mutant
if the predicted model indicates that the BChE variant should
have enhanced catalytic activity. The method includes gener

mutant BChE protein is then used in catalytic as says to deter

mine the catalytic ef?ciency against (—)-cocaine.
The use of predictive, computational modeling of the
present method for identifying mutant BChE candidates and
60

the resulting mutant BChE are novel and unexpected over

prior conventional methods which will now be readily appar

ating an initial structure of the transition state structure for the

ent to one of ordinary skill in the art.

rate-determining step for the cocaine hydrolysis catalyzed by

Using the present method, most discovered new mutants
include a speci?c mutation (Y332G) on residue #332. No
prior BChE mutant having the Y332G mutation had ever been
reported previously; only mutations Y332A and Y332M on
residue #332 had been tested previously by other researchers.

a possible BChE mutant. A suf?ciently long time molecular
dynamics simulation is performed on the transition state
structure in water to have a stable molecular dynamics traj ec

tory. The molecular dynamics trajectory is analyzed and the

65
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Prior to the present invention, there Was no reason to expect

ics simulations Were only performed on the cocaine binding
With the Wild-type BChE. As is shoWn beloW in the folloWing

that a mutant includingY332G mutation should be better than
the corresponding mutant including Y332A mutation or
Y332M. Thus, the present mutants With a Y332G mutation

experiments, the computational prediction could be com

pletely Wrong Without directly modeling and simulating

Which have enhanced cataltytic activity represent a surprising

cocaine binding With the proposed mutants.

and unexpected result over prior BChE mutants.
A Y332G mutant (single mutation) Was ?rst tested and
found that the Y332G mutant had a slightly loW (or approxi

the folloWing non-limiting examples in the form of experi

The present invention Will noW be discussed With regard to

mately equal) catalytic ef?ciency than the Wild-type. So, only

ments Which are provided to enhance understanding of the
present invention but in no Way limit its scope or applicability.

an appropriate combination of different mutations on differ
ent residues could make the enZyme more active. As seen

EXPERIMENT 1

beloW, the prior art did not reveal that any of the particular
combinations tested Was expected to have an improved cata

Computational Study of Cocaine Binding With

lytic ef?ciency. The present method is based on the present

Wild-Type and Mutant BChE’s for A328W/Y332G,
A328W/Y332A, and A328W/Y332A/Y419S

unique, extensive computational modeling and simulations of
the detailed catalytic mechanism for both the Wild-type BChE

A detailed computational study of cocaine binding With

and the mutants.

The primary improvement of the present method over the

prior art is that high-performance computational modeling
and simulations of the detailed catalytic mechanism are per

20

formed, Which includes modelinig hoW cocaine binds With
BChE and the subsequent structural transformation and
chemical reaction process. The prior art only considered the
cocaine binding With the enZyme (BChE) and Was unable to
examine the detailed catalytic reaction process after the
BChE-cocaine binding. When molecular modeling Was lim
ited to studying the BChE-cocaine binding, one could only
design a mutation to improve the BChE-cocaine binding

Y332A, and A328W/Y332A/Y419S, as simple geometric
consideration of the binding site suggests that these mutations
could be important for changing the (—)-cocaine rotation from

the non-prereactive complex to the prereactive complex. Wet
25

experimental tests Were conducted on the catalytic activity of
these mutants for (—)-cocaine in order to verify the computa
tional predictions. All of the obtained results clearly demon
strate that molecular modeling and MD simulations of

30

putational approach to the rational design of high-activity

Without knowing Whether the mutation Will also speedup the
subsequent chemical reaction process or not.

cocaine binding With BChE mutants provide a reliable com

To overcome the obstacles of prior challenges to using

mutants of BChE for the (—)-cocaine hydrolysis.
3D model of BChE. The initial coordinates of human
BChE used in the computational studies came from the X-ray
crystal structure deposited in the Protein Data Bank (pdb

computational techniques such as molecular docking and
molecular dynamics simulation previously used by others
Which Were based on an empirical force ?eld Which cannot be

used to perform necessary reaction coordinate calculations
for the catalytic reaction process, a variety of state-of-the-art

35

computational techniques of homology modeling, molecular
docking, molecular dynamics, quantum mechanics (QM),
40

eters.

Molecular docking. Molecular docking Was performed for

each non-prereactive protein-ligand binding complex. The
45

process and the corresponding energetics. These extensive
computational modeling and simulation studies provided for
the rational design of possible BChE mutants that not only

binding site Was de?ned as a sphere With an approximately 15

A radius around the active site residue S198. The amino acid
residues included in the binding site model are not contiguous
in the protein. Cocaine, considered as a ligand, Was initially
positioned at 17 A in front of S198 of the binding site. Each

can improve the BChE-cocaine binding, but also can speedup
the subsequent chemical reaction process. As a result, one can

1993, 234, 779, herein incorporated by reference, and
lnsightll softWare (Accelrys, Inc.) with the default param

ing QM and QM/MM, led to the study of the detailed reaction
coordinate of the BChE-catalyzed hydrolysis of cocaine
Which, for the ?rst time, provided the detailed structures of all
transition states and intermediates existing in the reaction

code: 1POP). The missing residues (D2, D3, E255, D378,
D379, N455, L530, E531, and M532) in the X-ray crystal
structure Were built using the automated homology modeling
tool Modeler disclosed by Sali, A.; Blundell, T. L. J. Mol.
Biol. 1990, 212 403, and Sali, A.; Blundell, T. L. J. Mol. Biol.

and hybrid quantum mechanics/molecular mechanics (QM/
MM) Were used for the rational design of the BChE mutants.
The combined use of these computational techniques, includ

Wild-type and mutant BChE’s starting from the available
X-ray crystal structure of Wild-type BChE Was performed.
The simulated mutants include A328W/Y332G, A328W/

50

BChE-cocaine binding complex Was energy-minimized by

noW quickly discover the BChE mutants With the signi?

using the steepest descent algorithm ?rst until the maximum

cantly improved catalytic ef?ciency.

energy derivative is smaller than 4 kcal/mol/A and then the

In addition, to the differences mentioned above, the present
molecular modeling of the BChE-cocaine binding also differs

conjugated gradient algorithm until the maximum energy

from the prior modeling. The molecular modeling in the prior

55

art considered only one binding mode for each BChE-cocaine

system, Without modeling the possible cocaine rotation in the
BChE active site after the binding. The present method con
siders tWo different binding modes for each BChE-cocaine
system and the structural transformation betWeen them: non

60

prereactive and prereactive BChE-cocaine complexes. The

implemented in the Discoveri3/lnsightll calculation engine,
disclosed by Cornell, W. D.; Cieplak, P.; Bayl), C. 1.; Gould,
I. R.; MerZ, Jr, K. M.; Ferguson, D. M.; Spellmeyer, D. C.;

present modeling provides more detailed information about
the BChE-cocaine binding and the subsequent structural
transformation.

The present method includes molecular dynamics simula
tions performed on the cocaine binding With both the Wild
type BChE and the mutants Whereas prior molecular dynam

derivative is smaller than 0.001 kcal/mol/A. The energy mini
miZation Was folloWed by a 300 ps molecular dynamics (MD)
simulation at T:298 K With a time step of 1 fs. During the
energy minimization and MD simulation, only cocaine and
the residues of BChE included in the binding site Were
alloWed to move, While the remaining part of the protein Was
?xed. The energy-minimization and MD simulation for these
processes Were performed by using the Amber force ?eld

65

Fox, T.; CaldWell, J. W.; Kollman, P. A. J. Am. Chem. Soc.
1995, 117, 5179. The non-bonded cut-off method and the
dielectric constant Were set up to group based (12 A cut-off
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distance) and distance dependent, respectively (E:4r) in

Most of the MD simulations in Water Were performed on a

accordance With Harvey, S. C. Proteins 1989, 5, 78-92, herein

supercomputer, Superdome (shared-memory, With 4 nodes

incorporated by reference.

and 256 processors), at the Center for Computational Sci
ences, University of Kentucky. The other computations Were

Molecular dynamic simulation in Water. The initial coor

dinates used in the MD simulation of the non-prereactive

carried out on SGI Fuel Workstations and a 34-processors

complexes Were determined by using the molecular docking
procedure described above, Whereas the initial coordinates

IBM x335 Linux cluster.

used in the MD simulation of the prereactive complexes Were

human BChE cDNA Was performed by the QuikChange
method of Braman, 1.; PapWorth, C.; Greener, A. Methods
Mol. Biol. 1996, 57, 5731, herein incorporated by reference.

Experimental procedure. Site-directed mutagenesis of

obtained from superimposing backbone of the X-ray crystal
structure to that of the previously disclosed simulated prere
active complex of Zhan et al betWeen cocaine and a homology
model of Wild-type BChE. Each BChE-cocaine binding com
plex Was neutraliZed by adding tWo chloride counterions and

Mutations Were generated from Wild-type human BChE in a

pRc/CMV expression plasmid in accordance With Xie, W.;
Altamirano, C. V.; Bartels, C. F.; Speirs, R. 1.; Cashman, 1. R.;

Was solvated in a rectangular box of TIP3P Water molecules

With a minimum solute-Wall distance of 10 A. The general
procedure for carrying out the MD simulations in Water is
similar to that used in our previously reported other compu
tational studies such as those in Zhan et al and (a) Zhan, C.-G.;

Lockridge, 0. Mol. Pharmacol. 1999, 55, 83, all herein incor

porated by reference, kindly provided by Dr. Lockridge at
University of Nebraska Medical Center. Using plasmid DNA
as template and primers With speci?c base-pair alterations,

Norberto de SouZa, O.; Rittenhouse, R.; Ornstein, R. L. J Am.

Chem. Soc. 1999, 121, 7279, (b) Koca, 1.; Zhan, C.-G.; Rit

20

tenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 2001, 123,

mutations Were made by polymerase chain reaction With Pfu

817, (c) Koca, 1.; Zhan, C.-G.; Rittenhouse, R. C.; Ornstein,

DNA polymerase, for replication ?delity. The PCR product

R. L.J Compul. Chem. 2003, 24, 368, herein all incorporated
by reference. These simulations Were performed by using the
Sander module of Amber7 program as taught by Case, D. A.;
Pearlman, D. A.; CaldWell, 1. W.; Cheatham III, T. E.; Wang,
1.; Ross, W. S.; Simmerling, C. L.; Darden, T.A.; MerZ, K. M.;
Stanton, R. V.; Cheng, A. L.; Vincent, 1. 1.; CroWley, M.; Tsui,

Was treated With Dpn I endonuclease to digest the parental
DNA template. Modi?ed plasmid DNA Was transformed into
25

sequences of the mutants Were con?rmed by DNA sequenc

ing. BChE mutants Were expressed in human embryonic kid

V.; Gohlke, H.; Radmer, R. 1.; Duan,Y.; Pitera, 1.; Massova, I.;
Seibel, G. L.; Singh, U. C.; Weiner, P. K.; Kollman, P. A.
(2002), AMBER 7, University of California, San Francisco,
herein incorporated by reference. The solvated system Was
optimiZed prior to the MD simulation. First, the protein

ney cell line 293T/ 17. Cells Were groWn to 80-90% con?u
30

ligand Was froZen and the solvent molecules With counterions
Were alloWed to move during a 5000-step minimiZation With

35

the conjugate gradient algorithm and a 5 ps MD run at T:300
K. After full relaxation and the entire solvated system Was

benZoic acid, the product of cocaine hydrolysis by BChE, We
40

Was repeated for each mutant. The MD simulations Were

45

dance With Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.;
Fortier, P.-L.; Albaret, C.; Lockridge, 0. Biochim. Biophys.
Acla 1999, 1433, 281, herein incorporated by reference. In

for varying times. Reactions Were stopped by adding 300 pl of
50

0.02 M HCl, Which neutraliZed the liberated benZoic acid
While ensuring a positive charge on the residual cocaine.
[3H]benZoic acid Was extracted by 1 ml of toluene and mea

55

dependent radiometric data Were ?tted to the kinetic equation
so that the catalytic ef?ciency (km/KM) Was determined.
Depicted in FIG. 1 are plots of some important distances in

adjusted by isotropic position scaling. The particle mesh
EWald (PME) method of Essmann, U.; Perera, L.; BerkoWitZ,
M. L.; Darden, T. A.; Lee, H., Pedersen; L. G. J. Chem. Phys.
1995, 98, 10089, herein incorporated by reference, Was used

used sensitive radiometric assays based on toluene extraction
of [3 H] cocaine labeled on its benZene ring Were used in accor

brief, to initiate reactions, 100 nCi of [3H]cocaine Was mixed
With 100 pl of culture medium. Reactions proceeded at 370 C.

1984, 81, 3684, herein incorporated by reference. The
SHAKE algorithm of Ryckaert, 1. P.; Ciccotti, G.; Berendsen,
H. C. J. Comp. Phys. 1977, 23, 327 (herein incorporated by
reference) Was applied to ?x all covalent bonds containing a
hydrogen atom, a time step of 2 fs Was used, and the non-bond
pair list Was updated every 10 steps. The pressure Was

Were incubated at 370 C. in a C02 incubator for 24 hours and
cells Were moved to 60-mm culture vessel and cultured for
four more days. The culture medium [10% fetal bovine serum

in Dulbecco’s modi?ed Eagle’s medium (DMEM)] Was har

K to T:300 K in 30 ps before the production MD simulation

performed With a periodic boundary condition in the NPT
ensemble at T:300 K With Berendsen temperature coupling
and constant pressure (P:1 atm) With isotropic molecule
based scaling disclosed in Berendsen, H. C.; Postma, 1. P. M.;
van Gunsteren, W. F.; DiNola, A.; Haak, 1. R. J. Comp. Phys.

ence in 6-Well dishes and then transfected by Lipofectamine
2000 complexes of 4 ug plasmid DNA per each Well. Cells

vested for a BChE activity assay. To measure cocaine and

energy-minimized, the system Was sloWly heated from T:10

for 500 ps. The full minimization and equilibration procedure

Escherichia coli, ampli?ed, and puri?ed. The DNA

sured by scintillation counting. Finally, the measured time

to treat long-range electrostatic interactions. A residue-based
cutoff of 10 A Was applied to the noncovalent interactions.

During the 500 ps production MD simulation, the coordinates

the MD-simulated (—)-cocaine binding With A328W/Y332G

of the simulated complex Were saved every 1 ps.

60

Molecular docking and MD simulation procedures
described above Were performed to study cocaine binding
With Wild-type BChE and three mutants, i.e., A328W/
Y332A, A328W/Y332A/Y419S, and A328W/Y332G. For
each protein system (Wild-type or mutant BChE), the protein

65

BChE versus the simulation time, along With root-mean
square deviation (RMSD) of the coordinates of backbone
atoms in the simulated structure from those in the X-ray
crystal structure. MD trajectories for other complexes Were
similar to these tWo in FIG. 1, although the simulated average
distances are different. Summarized in Table 2 are the average

binding With cocaine Was considered in both the non-prere

values of some important geometric parameters in the simu

active and prereactive enZyme-substrate complexes.

lated complexes.
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structure of Nicolet et al, one can see from FIG. 1 that the

TABLE 2

RMSD values are all smaller than 1.3 A for the whole protein
BChE-cocaine
binding“

<D1>non D1>

wild-type
wild-type with

structures.

Average values
of the geometric parametersC

5.60
7.64

.27
.69

D2>

D3>

D4>

.77
.88

.71
.30

.37
.83

RMSD‘!

The MD simulations of the prereactive complexes reveal

®> nonpre

re

67
61

.27
.13

1.14
1.15

that wild-type BChE binding with (—)-cocaine is essentially
the same as the binding with (+)-cocaine in the binding site,
except for the different positions of methyl ester group of the
substrates. The simulated average distances between the car

(+)—cocainel7

bonyl carbon of the benzoyl ester and S198 OY are 3.27 and

A328W/Y332A

7.11

.87

.30

.14

.01

51

1.58

1.65

3.69 A for (—)-cocaine and (+)-cocaine, respectively. More

A328W/Y332G

7.06

.96

.28

.52

.42

60

1.20

.35

A328W/Y332N

5.18

.84

.64

.56

.97

64

2.66

.62

over, the (+)-cocaine is stabilized more effectively by the
formation of strong hydrogen bonds with the backbone NH of
residues G116, G117, and A199 as summarized above in

“Refers to (—)-cocaine binding with wild-type human BChE or (—)-cocaine binding with a
mutant BChE, unless indicated otherwise.

perpendicular to S198 C40Y with a dihedral angle 6) of ~670

bRefers to (+)-cocaine binding with wild-type human BChE.

and ~61° for (—)- and (+)-cocaine, respectively.

C<D1>wn and <D1> represent the average distances between the S198 O1 atom and the
carbonyl carbon of the cocaine benzoyl ester in the simulated non-prereactive and prereac
tive BChE-cocaine complexes, respectively. <D2>, <D3 >, <D4> refer to the average values
ofthe simulated distances from the carbonyl oxygen ofthe cocaine benzoyl ester to the NH 20
hydrogen atoms ofG116, G117, andA199 residues, respectively. <®> is the average ofthe
dihedral angle formed by the S198 O1 atom and the plane ofthe carboxylate group ofthe
cocaine benzoyl ester. See Scheme 2.
“The root-mean-square deviation (RMSD) of the coordinates of backbone atoms in the
simulated structure from those in the X-ray crystal structure ofBChE. “nonpre” and “pre”

A comparison was made between the currently simulated
structures of the BChE-cocaine binding with those simulated
previously by using a homology model of BChE and it was
noted that two major differences between the two sets of

Y419S

Table 2. The cocaine benzoyl ester moiety is positioned quasi

refer to the non-prereactive and prereactive BChE-cocaine complexes, respectively.

(—)- and (+)-cocaine binding with wild-type BChE. FIG. 2

25

shows the binding structures of the simulated non-prereactive

and prereactive complexes of wild-type BChE binding with

Zhan et al. The RMSD of the coordinates of backbone atoms

the two enantiomers of cocaine. In the non-prereactive com

plexes with (—)- and (+)-cocaine, the methyl ester group of

structures. By using the X-ray crystal structure in accordance
with Nicolet et al, the acyl loop is positioned on the top of the
cocaine benzoyl ester moiety of the cocaine, whereas the acyl
loop is far from the cocaine benzoyl ester moiety in the
structure simulated starting from the homology model of

in the previously simulated prereactive BChE-(—)-cocaine
30

cocaine is positioned at the top of the H438 backbone, while

the cocaine benzoyl ester moiety is quasi-parallel to the
C40Y side chain of S198 with a dihedral angle 6) of —80 and

140°, respectively.
35

complex from those in the X-ray crystal structure of BChE is
~2.0 A for the entire protein and ~3 .0 A for the acyl loop. The
RMSD value became ~2.4 A for the entire protein and ~3.3 A
for the acyl loop, when the X-ray crystal structure was

replaced by the MD-simulated prereactive BChE-(—)-cocaine
complex starting from the X-ray crystal structure. Despite
these structural differences, the benzoyl ester group of the
ligand is still close to the key residues (S197, G116, and
G1 17) in the BChE binding site. Some signi?cant differences

Scheme 2. Hydrolysis of (—)—cocaine and (+)—cocaine.

are associated with the distances between the S198 OY atom
40

45

and the carbonyl carbon of the cocaine benzoyl ester in non

prereactive complexes. The average values of this distance in
the non-prereactive complexes were ~9.5 and ~8.5 A for (—)
and (+)-cocaine, respectively, when a homology model was
used. Using the X-ray crystal structure to conduct the analy
sis, corresponding average values became ~5.6 and ~5.2 A,

respectively. Therefore, both (—)- and (+)-cocaine became
closer to the binding site when the homology model was

replaced by the X-ray crystal structure. However, no signi?
50

55

Here, 6) refers to the dihedral angle formed by S198 0V and
the plane of carboxylate group of the cocaine benzoyl ester as
shown in the structure diagram below.
The simulated internuclear distances between the carbonyl
oxygen of cocaine benzoyl ester group and the NH hydrogen
of G1 16, G117, and A199 are comparable for the two enan
tiomers. The simulated average distances between the carbo
nyl carbon of the benzoyl ester and S198 OY are 5.60 A and

cant changes of the binding in the prereactive complexes were
observed when the used homology model was replaced by the
X-ray crystal structure. The average values of the simulated
distance between the S198 OY atom and the carbonyl carbon
of the cocaine benzoyl ester in the prereactive complexes are
always close to ~3 .5 A for both (—)- and (+)-cocaine no matter
whether the X-ray crystal structure or homology model of
BChE was used as the starting structure. The similar compu

60

tational results obtained from the use of the X-ray crystal
structure and homology model of BChE provides evidence
that the fundamental structural and mechanistic insights
obtained from the previous computational studies of Zhan et
al are reliable, despites the previous simulations were per

formed by using the homology model when the X-ray crystal
65

structure was not available.

5.18 A for (—)- and (+)-cocaine, respectively. Comparing the

Further, the simulated structures of the non-prereactive

simulated protein backbone structures to the X-ray crystal

BChE-cocaine complexes were superimposed with the cor

US 8,399,644 B1
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responding prereactive complexes. As shown in FIG. 3, the

and 6.97 A; no any hydrogen bond betWeen them. In addition

(—)-cocaine rotation in the BChE active site from the non

to the internuclear distances, another interesting geometric
parameter is the dihedral angle, 6), formed by S198 0V and the
plane of the carboxylate group of the cocaine benZoyl ester.

prereactive complex to the prereactive complex is hindered
by some residues as the positions ofY332, A328, and F329
residues in the non-prereactive complex are signi?cantly dif
ferent from the corresponding positions in the prereactive
complex, Whereas none of these residues hinders the (+)

As seen in Table 2, the 6) values in the prereactive complexes
of cocaine With Wild-type BChE and all of the BChE mutants
other than A328W/Y332A/Y419S BChE all slightly deviate
from the ideal value of 900 for the nucleophilic attack of S 1 98
0V at the carbonyl carbon of cocaine. The 6) value in the

cocaine rotation in the BChE active site from the non-prere

active complex to the prereactive complex because these resi
dues stay in nearly the same positions in the tWo BChE-(+)

prereactive complex of (—)-cocaine With A328W/Y332A/

cocaine complexes.

Y419S BChE is 164°, Which is considerably different from

(—)-cocaine binding With BChE mutants. NoW that the
(—)-cocaine rotation from the non-prereactive complex to the
prereactive complex has been knoWn to be the rate-determin
ing step of the BChE-catalyzed hydrolysis of (—)-cocaine as

the ideal value of 90°.

shoWn by Zhan et al, useful BChE mutants should be
designed to speci?cally accelerate the change from the non

non-prereactive complex to the prereactive complex, the rate

prereactive BChE-(—)-cocaine complex to the prereactive

cocaine, should be loWer than that in the Wild-type BChE.
Thus, the MD simulations predict that both A328W/Y332A
and A328W/Y332G BChE’s should have a higher catalytic

Catalytic activity. The aforementioned discussion provides
evidence that the energy barriers for the (—)-cocaine rotation
in A328W/Y332A and A328W/Y332G BChE’s from the

determining step for the BChE-catalyzed hydrolysis of (—)

complex. The question is Whether MD simulation can be

performed to help design BChE mutants that have higher

20

catalytic activity for (—)-cocaine hydrolysis.

activity than the Wild-type BChE for (—)-cocaine hydrolysis.

In the simulated non-prereactive complex, the average dis
tance betWeen the carbonyl carbon of cocaine benZoyl ester
and S198 0V is 7.6 A forA328W/Y332A BChE and 7.1 A for

Further, the MD simulations also suggest that the energy
barrier for the (—)-cocaine rotation in A328W/Y332G BChE
should be slightly loWer than that in A328W/Y332A BChE

A328W/Y332G BChE, as seen in Table 2 above. In the simu

25

lated prereactive complex, the average values of this impor

the activity of A328W/Y332A BChE. In addition, the MD
simulations predict that A328W/Y332A/Y419S BChE

tant internuclear distance become 3.87 and 3.96 A for

A328W/Y332A and A328W/Y332G BChE’s, respectively.
Compared to the simulated Wild-type BChE-(—)-cocaine pre
reactive complex, the average distances betWeen the carbonyl

and, therefore, the catalytic activity ofA328W/Y332G BChE
for the (—)-cocaine hydrolysis should be slightly higher than
should have no catalytic activity, or have a considerably loWer

30

catalytic activity than the Wild-type, for (—)-cocaine hydroly

carbon of the cocaine benZoyl ester and S198 0V in the pre

sis because (—)-cocaine binds With the mutant BChE in a Way

reactive complex of (—)-cocaine With A328W/Y332A and

that is not suitable for the catalysis.

A328W/Y332G BChE’s are all slightly longer, Whereas the
average distances betWeen the carbonyl oxygen of the
cocaine benZoyl ester and the NH of G1 16, G117, and A199
residues are all shorter. This provides evidence that (—)-co
caine more strongly bind With A328W/Y332A and A328W/

The catalytic ef?ciency (km/KM) of A328W/Y332A
BChE for (—)-cocaine hydrolysis Was reported to be 8.56><106
35

M H11I1_l,Wh1Ch1S 9.39 times ofthe kCat/KMvalue (9.11><105

prereactive complex to the prereactive complex did not cause

M min_l) of the Wild-type BChE. To examine these theoreti
cal predictions of the relative activity forA328W/Y332G and
A328W/Y332A/Y419S BChE’s, aA328W/Y332A, A328W/
Y332G, and A328W/Y332A/Y419S BChE Was produced
through site-directed mutagenesis. To minimize the possible
systematic experimental errors of the kinetic data, kinetic

considerable changes of the positions of A332 (or G332),

studies Were performed With all of three mutants under the

Y332G BChE’s in the prereactive complexes. More impor
tantly, the (—)-cocaine rotation in the active site of A328W/
Y332A and A328W/Y332G BChE’s from the non

40

W328, and F329 residues as seen in FIG. 4, compared to the

same condition and compared the catalytic ef?ciency of the

(—)-cocaine rotation in the active site of Wild-type BChE.
These results provide evidence that A328W/Y332A and

A328W/Y332G and A328W/Y332A/Y419S to that of the

A328W/Y332A for (—)-cocaine hydrolysis at benZoyl ester

A328W/Y332G BChE’s should be associated With loWer

group. Based on the kinetic analysis of the measured time

energy barriers than the Wild-type for the (—)-cocaine rotation

dependent radiometric data, the ratio of the kcat/KM value of

from the non-prereactive complex to the prereactive complex.
Further, (—)-cocaine binding With A328W/Y332G BChE is

A328W/Y332G BChE to the kcat/KM value of A328W/
Y332A BChE for the (—)-cocaine hydrolysis Was determined
to be ~2.08, or A328W/Y332G BChE has a kcat/KM value of

very similar to the binding With A328W/Y332A BChE, but

50

the position change of P329 residue caused by the (—)-cocaine

~1.78><107M min“1 for the (—)-cocaine hydrolysis. The radio

rotation Was signi?cant only in A328W/Y332A BChE, thus
suggesting that the energy barrier for the (—)-cocaine rotation
in A328W/Y332G BChE should be slightly loWer than that in
A328W/Y332A BChE.

metric data shoW no signi?cant catalytic activity for A328W/

55

Concerning (—)-cocaine binding With A328W/Y332A/

Conclusion. Molecular modeling, molecular docking, and
molecular dynamics (MD) simulations Were performed to

Y419S BChE,Y419 stays deep inside the protein and does not
directly contact With the cocaine molecule. The Y4 1 9S muta
tion Was tested because it Was initially expected that this
mutation Would further increase the free space of the active
site pocket so that the (—)-cocaine rotation could be easier.
HoWever, as seen in Table 2 above, the average distance

Y332A/Y419S BChE. These experimental data are consis
tent With the theoretical predictions based on the MD
simulations.

study cocaine binding With human butyrylcholinesterase
60

(BChE) and its mutants, based on a recently reported X-ray
crystal structure of human BChE. The MD simulations of
cocaine binding With Wild-type BChE led to average BChE
cocaine binding structures similar to those obtained recently

betWeen the carbonyl carbon of cocaine benZoyl ester and

from the MD simulations based on a homology model of

S198 OY atom in the simulated prereactive complex Was as

BChE, despite the signi?cant difference found at the acyl
binding pocket. This con?rms the fundamental structural and
mechanistic insights obtained from the prior computational

long as 5.84 A. The average distances betWeen the carbonyl
oxygen of the cocaine benZoyl ester and the NH hydrolysis
atoms of G116, G117, and A199 residues are betWeen 4.56
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studies of Zhan et al based on a homology model of BChE,
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e.g., the rate-determining step for BChE-catalyzed hydrolysis
of biologically active (—)-cocaine is the (—)-cocaine rotation

cocaine hydrolysis higher than that of Wild-type BChE and
the activity of A328W/Y332G BChE should be slightly
higher than that of A328W/Y332A BChE, Whereas A328W/
Y332A/Y4l9S BChE is expected to lose the catalytic activ
ity. The computational predictions are completely consistent
With the experimental kinetic data, providing evidence that
the used computational protocol, including molecular mod
eling, molecular docking, and MD simulations, is reliable in
prediction of the catalytic activity of BChE mutants for (—)
cocaine hydrolysis.

in the BChE active site from the non-prereactive BChE-(—)

cocaine complex to the prereactive complex.
The MD simulations further reveal that the (—)-cocaine
rotation in the active site of Wild-type BChE from the non

prereactive complex to the prereactive complex is hindered
by some residues such that the positions ofY332, A328, and
F329 residues in the non-prereactive complex are signi?
cantly different from those in the prereactive complex. Com

pared to (—)-cocaine binding With Wild-type BChE, (—)-co
caine more strongly bind With A328W/Y332A and A328W/

EXPERIMENT 2

Y332G BChE’s in the prereactive complexes. More
importantly, the (—)-cocaine rotation in the active site of

MD Simulations and Quantum
Mechanical/Molecular Mechanical (QM/MM)

A328W/Y332A and A328W/Y332G BChE’s from the non

prereactive complex to the prereactive complex did not cause
considerable changes of the positions of A332 or G332,
W328, and F329 residues. These results provide evidence that

Calculations Relating to a l995/A328W/Y332G

Mutant (Mutant l) (SEQ ID NO: 1)

A328W/Y332A and A328W/Y332G BChE’s are associated

With loWer energy barriers than Wild-type BChE for the (—)
cocaine rotation from the non-prereactive complex to the

20

Generally speaking, for rational design of a mutant enZyme
With a higher catalytic activity for a given substrate, one needs
to design a mutation that can accelerate the rate-determining

prereactive complex. Further, (—)-cocaine binding With

step of the entire catalytic reaction process While the other

A328W/Y332G BChE is very similar to the binding With

steps are not sloWed doWn by the mutation. Reported com

A328W/Y332A BChE, but the position change of P329 resi
due caused by the (—)-cocaine rotation Was signi?cant only in
A328W/Y332A BChE, thus suggesting that the energy bar
rier for (—)-cocaine rotation in A328W/Y332G BChE should

25

lyZed by Wild-type BChE as disclosed by Sun et al, Zhan et al

be slightly loWer than that in A328W/Y332A BChE. It has
also been demonstrated that (—)-cocaine binds With A328W/
Y332A/Y4l9S BChE in a Way that is not suitable for the

putational modeling and experimental data indicated that the
formation of the prereactive BChE-(—) -cocaine complex (ES)
is the rate-determining step of (—)-cocaine hydrolysis cata

30

and HamZa, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. J. Phys.
Chem. B 2005, 109, 4776, herein incorporated by reference,
Whereas the rate-determining step of the corresponding (+)

catalysis.

cocaine hydrolysis is the chemical reaction process consist

Based on the computational results, both A328W/Y332A
and A328W/Y332G BChE’s have catalytic activity for (—)

and shoWn in Scheme 3 and Scheme 4 beloW.

ing of four individual reaction steps disclosed by Zhan et al

